All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @candicebeasley on TikTok · 98s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @candicebeasley's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Alright, this is my third week, my third shot. I've already prepped the area.
  2. 0:04It is the M.O.
  3. 0:06wipe is proofed.
  4. 0:08Alright, and so pull the cap off.
  5. 0:11And turn about two inches from my navel.
  6. 0:23How do you have about five, six seconds.
  7. 0:36A little bit of cap back on.
  8. 0:39A little bit of blue up there.
  9. 0:41Mmm.
  10. 0:48So yesterday I started having some nausea.
  11. 0:52And, um, well, day before and I was having some gastric issues.
  12. 0:57And I wasn't having them before, so.
  13. 1:00I am having some gastric issues or some stuff going on that just started.
  14. 1:10So this is the end of technically yesterday's weekend.
  15. 1:13Week two.
  16. 1:15And today is my first day of week three.
  17. 1:17I am traveling next week.
  18. 1:20So I'll see how that goes.
  19. 1:23But as you can see, I am putting it in my sharpest container.
  20. 1:27And that's that.
  21. 1:29Alright, you guys, I'll be back with more information.
  22. 1:33But so far, just a little nausea.
  23. 1:36Alright, I'll see you next time.

@candicebeasley's Mounjaro injection routine, fact-checked

Candice B|1️⃣0️⃣K Goals

TikTok creator

12.4K viewsWatch on TikTok

Quick answer

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and, as Zepbound, for chronic weight management. The creator is in her third week at the starting 2.5 mg dose, a period when GI side effects commonly emerge as the drug begins meaningfully slowing gastric emptying. Nausea and gastrointestinal disturbance at this stage are expected adverse effects documented in registration trials, not signals of an unusual reaction.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @candicebeasley's Mounjaro injection routine, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@candicebeasley's Mounjaro injection routine, fact-checked" from Candice B|1️⃣0️⃣K Goals. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and, as Zepbound, for chronic weight management.

The reason this review is not generic is the source wording and the canonical claim label "glp1 day one of my week 3 injection of mounjaro take my shot wi." In this clip, the useful excerpt is: "Alright, this is my third week, my third shot." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GI side effects with tirzepatide typically peak during the early titration period (weeks two through four) and decrease over time for most patients, per Dahl et al.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and, as Zepbound, for chronic weight management.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and, as Zepbound, for chronic weight management. The creator is in her third week at the starting 2.5 mg dose, a period when GI side effects commonly emerge as the drug begins meaningfully slowing gastric emptying. Nausea and gastrointestinal disturbance at this stage are expected adverse effects documented in registration trials, not signals of an unusual reaction.
  • 31-39% of participants in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) reported nausea on tirzepatide, making Candice's experience statistically common, not unusual.
  • GI side effects with tirzepatide typically peak during the early titration period (weeks two through four) and decrease over time for most patients, per Dahl et al. (2023, Diabetes, Obesity and Metabolism).

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • 31-39% of participants in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) reported nausea on tirzepatide, making Candice's experience statistically common, not unusual.
  • GI side effects with tirzepatide typically peak during the early titration period (weeks two through four) and decrease over time for most patients, per Dahl et al. (2023, Diabetes, Obesity and Metabolism).
  • The Mounjaro pen should be held against the skin for at least six seconds per Eli Lilly's prescribing information; five seconds may risk incomplete dose delivery.
  • Injection site rotation is required to prevent lipohypertrophy, a buildup of subcutaneous tissue that impairs drug absorption; the American Diabetes Association Standards of Care (2023) lists this as essential practice.
  • Tirzepatide must be stored at 36-46 degrees Fahrenheit; travelers need to plan for temperature control and carry prescriber documentation for TSA and customs.
  • High-fat meals, large portions, and alcohol can worsen tirzepatide-related nausea; Nauck and D'Alessio (2022, Nature Reviews Endocrinology) note that dietary behavior around injection time significantly affects GI tolerability.
  • Personal injection vlogs provide real value for injection-anxious patients but are not a substitute for clinician-guided injection training, which should cover hold time, site rotation, and storage requirements.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @candicebeasley actually say?

Candice walked her followers through her third tirzepatide (Mounjaro) injection, demonstrating the technique: cap removal, two-inch navel clearance, a five-to-six-second hold, then disposal in a sharps container. She also flagged that "yesterday I started having some nausea" and "gastric issues" that weren't present in her first two weeks. The video is a personal experience log, not a medical tutorial, and she doesn't make strong clinical claims.

What's worth examining: her injection mechanics, her timeline for side effect onset, and whether her casual reporting of GI symptoms matches what the clinical data actually shows about tirzepatide's side effect profile.

Does the science back this up?

Yes, on the GI side effects. Nausea and gastrointestinal disturbance appearing around weeks two to four is well-documented in the tirzepatide trials, and her experience is consistent with that pattern.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) reported nausea in 31-39% of tirzepatide participants depending on dose, with GI adverse events most common during dose escalation periods. Mounjaro starts at 2.5 mg for the first four weeks before titration, meaning many users experience their first meaningful GI response right around week two to three, when the drug's cumulative effect becomes noticeable. A 2023 analysis by Dahl et al. in Diabetes, Obesity and Metabolism confirmed that GI side effects peak early and typically reduce over time for most patients. Candice's "just started" observation tracks with this pharmacokinetic curve. Her body is likely adjusting to the GIP and GLP-1 dual agonism that slows gastric emptying.

What did they get wrong (or right)?

Her injection technique is mostly reasonable, but the "five, six seconds" hold she describes is on the lower end of what's recommended. She got the two-inch navel clearance right, and sharps container disposal is exactly correct, full stop.

The potential issue: Eli Lilly's prescribing information and injection guides typically recommend holding the pen against the skin for at least six seconds to ensure full dose delivery, with some clinical pharmacists suggesting up to ten seconds. A rushed hold risks incomplete injection. It's a small detail, but for a video that functions as a how-to for 12,000 viewers, it matters. She also doesn't mention rotating injection sites, which is standard practice to avoid lipohypertrophy (subcutaneous tissue buildup that can impair drug absorption). The American Diabetes Association's Standards of Care (2023) specifically calls out site rotation as essential for injectable medications. To her credit, she doesn't overstate her results, doesn't prescribe anything, and is honest that side effects have started. That's more responsible than a lot of GLP-1 content on this platform.

What should you actually know?

GI side effects with tirzepatide are normal, usually temporary, and don't mean the medication is harming you. But they're also not trivial for everyone, and they can affect your ability to eat, travel, or function at work.

Candice mentions she's traveling next week, which is worth addressing. Traveling with injectable GLP-1 medications requires planning: temperature storage (tirzepatide should be kept at 36-46 degrees Fahrenheit), TSA documentation, and access to sharps disposal. The FDA allows patients to carry injectable diabetes medications on planes with documentation. More practically, nausea on tirzepatide is often worsened by high-fat meals, large portions, and alcohol, all common in travel contexts. A 2022 review by Nauck and D'Alessio in Nature Reviews Endocrinology noted that GI tolerability with dual GIP/GLP-1 agonists is strongly influenced by dietary behavior around injection time. If you're starting tirzepatide and experiencing what Candice describes, talk to your prescriber before adjusting your dose or stopping. Don't crowdsource your titration schedule from TikTok, including this video.

The bottom line

Candice's video is honest and reasonably accurate. Her GI side effect timeline matches the clinical literature. Her sharps disposal is correct. Her injection hold time is slightly short, and she skips site rotation advice, which matters for long-term users.

The bigger picture is that personal injection vlogs like this one fill a real information gap for people who are nervous about self-injection. That's not nothing. But they're not a substitute for clinical guidance, and the details that get glossed over, like hold time and site rotation, are exactly the kind of thing that a prescribing clinician or pharmacist should walk through with you before your first injection. If your provider didn't do that, ask them to.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Candice B|1️⃣0️⃣K Goals · TikTok creator

12.4K views on this video

Day one of my Week 3 injection of Mounjaro! Take my shot with me!! #mounjarojourney #mounjaroweight #fypシ #mounjarotuesdayinjection #Splice

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 31-39% of participants in the surmount-1 trial (jastreboff et al.,?

31-39% of participants in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) reported nausea on tirzepatide, making Candice's experience statistically common, not unusual.

What does the video say about gi side effects with tirzepatide typically peak during the early?

GI side effects with tirzepatide typically peak during the early titration period (weeks two through four) and decrease over time for most patients, per Dahl et al. (2023, Diabetes, Obesity and Metabolism).

What does the video say about the mounjaro pen should be held against the skin for?

The Mounjaro pen should be held against the skin for at least six seconds per Eli Lilly's prescribing information; five seconds may risk incomplete dose delivery.

What does the video say about injection site rotation?

Injection site rotation is required to prevent lipohypertrophy, a buildup of subcutaneous tissue that impairs drug absorption; the American Diabetes Association Standards of Care (2023) lists this as essential practice.

What does the video say about tirzepatide must be stored at 36-46 degrees fahrenheit; travelers need?

Tirzepatide must be stored at 36-46 degrees Fahrenheit; travelers need to plan for temperature control and carry prescriber documentation for TSA and customs.

What does the video say about high-fat meals, large portions,?

High-fat meals, large portions, and alcohol can worsen tirzepatide-related nausea; Nauck and D'Alessio (2022, Nature Reviews Endocrinology) note that dietary behavior around injection time significantly affects GI tolerability.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Candice B|1️⃣0️⃣K Goals, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.